Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab, Docetaxel, Oxaliplatin, S1 and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07902648Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of serplulimab, lenvatinib, docetaxel, oxaliplatin, tegafur + gimeracil + oteracil in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
serplulimablenvatinibdocetaxeloxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07902648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902648.